[Translation] A randomized, double-blind, placebo-controlled, dose-escalation phase Ib clinical trial evaluating the safety, tolerability, and preliminary efficacy of AA001 monoclonal antibody in Chinese patients with Alzheimer's disease-related mild cognitive impairment and mild Alzheimer's disease.
主要目的:评价AD源性MCI和轻度AD患者多次静脉滴注AA001单抗后的安全性及耐受性
次要目的:评价AD源性MCI和轻度AD患者多次静脉滴注AA001单抗后的药代动力学(PK)特征;评价AD源性MCI和轻度AD患者多次静脉滴注AA001单抗后的免疫原性;初步探索AD源性MCI和轻度AD患者多次静脉滴注AA001单抗后的有效性
[Translation] Primary Objective: To evaluate the safety and tolerability of multiple intravenous infusions of AA001 monoclonal antibody in patients with Alzheimer's disease (AD)-related microvascular inflammation (MCI) and mild Alzheimer's disease (AD).
Secondary Objectives: To evaluate the pharmacokinetic (PK) characteristics of multiple intravenous infusions of AA001 monoclonal antibody in patients with AD-related MCI and mild Alzheimer's disease (AD); to evaluate the immunogenicity of multiple intravenous infusions of AA001 monoclonal antibody in patients with AD-related MCI and mild Alzheimer's disease (AD); and to preliminarily explore the efficacy of multiple intravenous infusions of AA001 monoclonal antibody in patients with AD-related MCI and mild Alzheimer's disease (AD).